< Back to previous page
Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions
Journal Contribution - Journal Article
Aims: The vascular endothelial growth factor homologue placental growth factor (PlGF) is apleiotropic cytokine, with a pro-inflammatory activity. Previous gene-inactivation studiesrevealed that loss of PlGF delays atherosclerotic lesion development and inhibits macrophageinfiltration, but the activity of an anti-PlGF antibody (aPlGF mAb) has not been evaluated yet.Methods and Results: We characterized the potential of short-term delivery of aPlGF mAb ininhibiting lesion development in ApoE-deficient mice (apoE-/-) and in CD4:TGFßRIIDN x apoE-/-mice, a more severe atherosclerosis model. Short-term treatment of aPlGF mAb reducesearly atherosclerotic plaque size and inflammatory cell infiltration in the lesion.Conclusions: These pharmacological aPlGF mAb results confirm previous genetic evidencethat inhibition of PlGF slows down early atherosclerotic lesion development. Furthermore, thephenocopy of genetic and pharmacological loss-of-function strategies underscores thataPlGF acts by selectively neutralizing PlGF.
Journal: Cardiovascular Research
Pages: 29 - 36